Shares of the company are trading at $19.72 which is significantly above $17.07, the 50 day moving average and which is slightly above the 200 day moving average of $18.99. TD Asset Management Inc. now owns 33,770 shares of the company's stock worth $754,000 after buying an additional 2,800 shares in the last quarter. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.23. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.
Several other equities analysts have also issued reports on EDIT. Finally, ProShare Advisors LLC raised its stake in shares of Editas Medicine by 18.9% in the second quarter. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $102.29 on company shares. Editas Medicine has a 52 week low of $12.43 and a 52 week high of $29.20. The current consensus analyst recommendation is sitting at 2.40 on company shares. Cann started coverage on Editas Medicine in a report on Monday, July 17th.
(NASDAQ:EDIT) shares saw heavy trading volume with 1,767K shares changing hands in the last trading session. The business's quarterly revenue was down 16.0% on a year-over-year basis.
Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Wednesday, August 9th.
COPYRIGHT VIOLATION WARNING: "Editas Medicine, Inc". Revenue for the quarter also killed consensus, coming in at $3.1 Million, compared to the consensus of 2.4 Million. Of those transactions, there were 40,485 shares of EDIT bought and 5.05 million shares sold. The company now has a consensus rating of "Buy" and an average target price of $26.03. The stock now has a Market Cap of $14.76B. Bank of America Corp DE now owns 5,936 shares of the company's stock valued at $133,000 after buying an additional 2,489 shares during the period. As of quarter end American International Group Inc had acquired a total of 16,739 shares growing its stake by 395.6%.
After a recent spot-check, Editas Medicine, Inc. UBS Group AG now owns 78,217 shares of the company's stock valued at $1,746,000 after buying an additional 68,990 shares during the last quarter. The average volume stands around 0.79 million shares. Next quarter's EPS is expected be $-0.78 and the next full year EPS is anticipated to be $-3.20. Driehaus Capital Management has an ownership of 125,684 stocks of the firms shares valued $2,805,000 after scooping up an extra 79,104 shares through out the quarter. large institution funds own 67.87% of the firms stock. UBS Group AG boosted its stake in shares of Editas Medicine by 747.7% in the first quarter.
MGM Resorts International (NYSE:MGM) Volume Spiking Mid-session
Its down 0.01, from 0.88 in 2016Q3. 1,061 Andeavor (NYSE:ANDV) shares with value of $89,304 were sold by Peery Blane W. CLSA reissued an "outperform" rating on shares of MGM Resorts International in a research note on Friday, April 28th.
North Korea nuclear war unlikely, but risk is rising
A U.S. attack using its bases on Japan's main islands or Okinawa, for example, would bring Japan into any conflict, says Schuster. Andersen Air Force Base on Guam is where the U.S. keeps its B1-B bombers deployed to the Asia Pacific.
Wedbush Reaffirms "Buy" Rating for AMC Entertainment Holdings, Inc. (AMC)
Elk Creek Partners, LLC reduced its holdings by shedding 11,765 shares a decrease of 2.3% from 03/31/2017 to 06/30/2017. BNP Paribas Arbitrage SA boosted its position in shares of AMC Entertainment Holdings by 574.5% in the second quarter.
Equity analyst Oppenheimer added EDIT to its research portfolio with a rating of "Perform". The corporation posted ($0.65) EPS (EPS) for the period, falling below brokerage firms expectations of ($0.64) by $0.01. (NASDAQ:EDIT). Gerald Frank Cox, Chief Medical Officer purchased $56,600 worth of shares at an average price of $14.15 on June 2nd.
TRADEMARK VIOLATION NOTICE: This piece of content was published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States & worldwide copyright & trademark legislation. The legal version of this piece can be accessed at https://www.thestockobserver.com/2017/08/11/editas-medicine-inc-nasdaqedit-pt-set-at-27-00-by-j-p-morgan-chase-co.html.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions.
Kevin Bitterman, Director disclosed the sale of 1,000,000 shares of (EDIT). The shares were bought at an average price of $14.07 per share, for a total transaction of $492,450.00.
Editas Medicine, Inc is a genome editing company. Company shares were recently noted 4.04% off of the 50-day high and 45.91% away from the 50-day low.
From another technical standpoint, Editas Medicine, Inc. The Company is involved in treating patients with genetically defined diseases by correcting their disease-causing genes. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).